JP Morgan Chase’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PTCT
RI
JT
JP Morgan Chase's PTCT Position: Q2 2026 in Review
JP Morgan Chase increased its PTC Therapeutics (PTCT) stake by 98% in Q2 2026, buying an estimated $24.4M and bringing the position to 684,042 shares worth $56.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1389.
JP Morgan Chase first reported a position in PTCT in Q3 2014 and has held it in 45 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- JP Morgan Chase held 684,042 shares of PTC Therapeutics worth $56.1M as of Q2 2026.
- JP Morgan Chase bought 338,025 PTC Therapeutics shares in Q2 2026, an estimated $24.4M.
- PTC Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1389 holding.
- JP Morgan Chase first reported a position in PTC Therapeutics in Q3 2014 and has held it in 45 quarters since.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.